欧州連合 - デンマーク語 - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - fedme - antiobesity preparations, excl. diætprodukter - som et supplement til kost og motion til behandling af svært overvægtige patienter (bmi på 30 kg/m2), eller overvægtige patienter (bmi på 27 kg/m2) med tilhørende risikofaktor(er), såsom type 2-diabetes eller dyslipidaemia (se afsnit 5.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicinhydrochlorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastiske midler - caelyx pegyleret liposomal er anført:som monoterapi til patienter med metastatisk brystkræft, hvor der er en øget cardiac risiko;til behandling af fremskreden kræft i æggestokkene hos kvinder, der har undladt en første linje platin-baseret kemoterapi, og i kombination med bortezomib til behandling af progressive myelomatose patienter, der har modtaget mindst én tidligere behandling, og som allerede har gennemgået eller er uegnet for bone marrow transplantation;til behandling af aids-relateret kaposis sarkom (ks) i patienter med lavt cd4-tæller (.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

n.v. organon - alendronsyre, colecalciferol - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. fosavance reducerer risikoen for vertebrale og hoftebrud.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt (se afsnit 4.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - fedme - antiobesity preparations, excl. diætprodukter - som et supplement til kost og motion til behandling af svært overvægtige patienter (bmi på 30 kg/m2), eller overvægtige patienter (bmi på 27 kg/m2) med tilhørende risikofaktor(er), såsom type 2-diabetes eller dyslipidaemia (se afsnit 5.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - behandling af diabetes mellitus hos voksne, unge og børn i alderen 1 år og derover.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

viatris limited - sildenafilcitrat - hypertension, lunge - urologicals - adultstreatment af voksne patienter med pulmonal arteriel hypertension, der er klassificeret som funktionelle klasse ii og iii, til at forbedre det fysiske kapacitet. effekt har vist sig ved primær lunghypertension og lunghypertension associeret med bindevævssygdom. pædiatrisk populationtreatment af pædiatriske patienter i alderen 1 år til 17 år med pulmonal arteriel hypertension. effektivitet med hensyn til forbedring af motion kapacitet eller pulmonal hæmodynamik har været vist i primær pulmonal hypertension og pulmonal hypertension forbundet med medfødt hjertesygdom (se afsnit 5.

欧州連合 - デンマーク語 - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart insulin degludec - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn fra 2 år.